Press Releases Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
4.39 ^USD	-3.09%		-20.18%	+32.23%

May. 16	UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating	MT
May. 07	HC Wainwright Adjusts Price Target on Rani Therapeutics Holdings to $13 From $12, Maintains Buy Rating	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Rani Therapeutics : 2024 DDW Oral Ustekinumab	May. 28	PU
Rani Therapeutics to Participate in May Investor Conferences	May. 14	AQ
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024	May. 09	AQ
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update	May. 06	AQ
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update	Mar. 20	AQ
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results	Mar. 18	AQ
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results	Mar. 15	AQ
Rani Therapeutics : RT-111 Phase 1 Data Presentation	Mar. 12	PU
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)	Feb. 05	AQ
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)	Jan. 09	PR
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist	Dec. 14	AQ
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update	Nov. 08	AQ
Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results	Nov. 01	AQ
The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study	23-10-25	AQ
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study	23-10-19	AQ
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research	23-10-12	AQ
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)	23-09-18	AQ
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies	23-09-07	AQ
Rani Therapeutics to Participate in September Investor Conferences	23-09-06	AQ
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update	23-08-11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Press Releases

Filters